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Scope and methodology
Oral anticoagulants are used to prevent and treat a wide
range of thromboembolic diseases. Currently available
oral anticoagulants include the vitamin K antagonists
(VKAs), such as warfarin. VKAs reduce the synthesis of
functional vitamin K-dependent factors (factor II, FVII,
FIX, FX, as well as protein C and protein S) by interfer-
ing with the vitamin K redox cycle. The newer oral anti-
coagulants (dabigatran, rivaroxaban, apixaban, edoxaban,
and betrixaban) each directly inhibit an activated clotting
factor, either FIIa or FXa. Their pharmacokinetic and
pharmacodynamic properties are more predictable than
those of the VKAs, so routine monitoring of the antico-
agulant effect is not required [1].
Various terms have been used to describe the ‘new’
class of oral anticoagulants, although they are not so new
or novel any more. Terms that are commonly encoun-
tered in the medical literature include: novel/new oral
anticoagulants (NOACs), direct oral anticoagulants (DO-
ACs), and target-specific oral anticoagulants (TSOACs).
However, the use of multiple terms and abbreviations can
lead to fragmentation of the medical literature, and con-
fusion among providers and patients. The term NOAC
has been used the longest, and, recently, some have
argued for use of the term ‘non-VKA oral antagonists’
(NOACs), to take advantage of the commonly used
abbreviation without using the terms novel and new [2].
However, identifying a class of drugs by what they are
not is scientifically unappealing. Perhaps more importantly,
there is at least one reported account where the term NOAC
written in the medical record was interpreted as meaning
‘No AntiCoagulation,’ potentially resulting in the patient
not receiving the critical therapy that was intended [3].
There is a clear need to reach a consensus on the
nomenclature of oral anticoagulants, and several experts
have called for consensus around the nomenclature for
oral anticoagulants [2,4–7].
We aimed to develop guidance from the Control of
Anticoagulation SSC of ISTH on the most appropriate
abbreviation for the newer/novel/target-specific/direct-act-
ing oral anticoagulants by seeking the opinions of throm-
bosis and anticoagulation thought leaders.
We administered a web-based survey (Data S1) to the
leaders (primarily board members) of 16 thrombosis, he-
mostasis, anticoagulation and vascular medicine societies
from seven different countries in North America and Eur-
ope (150 recipients in total) in September 2014. These
societies were selected on the basis of their clinical inter-
ests in vascular medicine, thrombosis, or anticoagulation.
All medical officers of each society whose contact infor-
mation was available were invited to participate in the
survey. Two reminders were sent to each participant, and
those who participated were not compensated. Of the 150
recipients, 77 (51%) completed the survey. In this survey,
we asked about their opinion regarding: (i) the need for
consensus around oral anticoagulation nomenclature; (ii)
concerns about the safety of using the term NOAC; and
(iii) their preferred term to describe this new class of oral
anticoagulants. On the basis of these survey results, the
following guidance statements were formulated.
The vast majority (89.6%) of the respondents felt that
there was a need to reach a consensus on terminology.
There was less agreement regarding the safety issue of the
term NOAC; 54.7% felt that there should be limited use
of this term. When the respondents were asked about the
single best term (DOAC [direct oral anticoagulant],
NOAC [non-VKA oral anticoagulant], NOAC [novel oral
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anticoagulant], ODI [oral direct inhibitor], SODA [specific
oral direct anticoagulant], TSOAC [target specific oral anti-
coagulant], and Other) for this class of medications, the top
three responses were as follows: DOAC (direct oral anti-
coagulant), 29.9%; NOAC (non-VKA oral anticoagulant),
28.6%; and TSOAC (target-specific oral anticoagulant),
23.4%. When the respondents were asked to select all
acceptable terms, the top three responses were as follows:
DOAC, 58.4%; TSOAC, 49.4%; and NOAC, 39.0%.
Concerns with the term NOAC
Anticoagulants are known to reduce the morbidity and
mortality associated with a number of thrombotic condi-
tions. In each of these conditions, lack of anticoagulant
therapy can have dramatic effects on patient outcomes.
In some reports, use of the term NOAC has been misin-
terpreted as ‘No AntiCoagulation’, which may lead to the
inadvertent omission of important anticoagulant therapy
for a patient with a thrombotic disorder [3]. In our sur-
vey, only 41 (54.7%) respondents agreed that the term
NOAC had safety implications that should limit its use.
This is not surprising, because many physicians would
not necessarily agree that many of the terms considered
to be unsafe by the Institute for Safe Medical Practices
are really unsafe [8]. Some have argued that the term
NOAC should be used and evolve, and that the ‘N’
should represent Non-VKA antagonist instead of new/
novel, because this terminology is well established in the
medical literature [5]. However, many experts also feel
that, ideally, a class of medications should be defined by
a positive characteristic or general mode of action, rather
than by a negative property that is lacking.
Despite the frequent adoption of NOAC in the medical
literature, and calls by some thrombosis and anticoagula-
tion leaders to use non-vitamin K oral anticoagulant
(NOAC), we feel that the potential safety implications
and lack of pharmacologic specificity of this abbreviation
should prevent its widespread use. Additionally, although
some have encouraged the use of non-VKA OAC as the
best term, we feel that this is both cumbersome and too
easily abbreviated as NOAC by clinicians and in the liter-
ature, with the safety implications noted above.
Recommendation statements for consensus around oral
anticoagulation nomenclature and harm with NOAC
1 We suggest that consensus be reached on a single term
to be used for describing the direct oral FIIa and FXa
inhibitors.
2 We recommend that a single term be used consistently
for all oral direct anticoagulants that have inherently
different mechanisms and clinical properties from those
of vitamin K antagonists.
3 We suggest that the abbreviation NOAC should not be
used to describe any class of oral anticoagulant.
Evidence for the use of DOAC
Unlike VKAs, the direct oral anticoagulants target one
specific factor (currently either FXa or FIIa). Specifically,
dabigatran inhibits thrombin (FIIa), whereas rivaroxaban,
apixaban, edoxaban and betrixaban all inhibit FXa. Use
of the term ‘direct’ adequately distinguishes this class of
medications from the VKAs, and allows each of these
medications to be discussed on the basis of their similar
(but not exactly the same) clinical profiles. In our survey,
DOAC received the most votes (45, 58.4%) as an accept-
able term for this class of medications. When respondents
were asked to pick the single best term, however, no sin-
gle choice dominated. Twenty-three (29.9%) respondents
selected DOAC, 22 (28.6%) selected NOAC (non-VKA
oral anticoagulant), and 18 (23.4%) selected TSOAC.
With low support for TSOAC in this survey of thrombo-
sis and anticoagulation experts, this term was not felt to
be the best single choice for routine use.
Given the potential safety limitations associated with the
use of NOAC and the relative specificity of pharmacologic
action, DOAC is a reasonable choice. DOAC is also used
widely in the published literature, making it a very reason-
able selection [6,9–11]. Many respondents commented that
the best descriptive term is one that describes the mecha-
nism of action, such as direct thrombin inhibitor and direct
FXa inhibitor. However, given the many similarities
between the oral agents of these two groups, it seems
reasonable to describe them together for the majority of
clinical scenarios. Nevertheless, they can be distinguished
by their mechanism of action in situations where it is
clinically relevant (e.g. selecting appropriate coagulation
laboratory testing and for potential medication strategies).
Recommendation statement for the use of DOAC
1 We suggest using the term ‘direct oral anticoagulant’
(DOAC) to reference the class of oral anticoagulants
that directly inhibit a single target and have similar
clinical properties (e.g. dabigatran, rivaroxaban, apix-
aban, edoxaban, and betrixaban).
2 We suggest that a drug’s specific mechanism of action
(e.g. direct FXa inhibitor or direct thrombin inhibitor)
should be used when it is clinically important to distin-
guish between the various DOAC medications.
Society endorsements
This guidance statement was written by the authors on
behalf of the ISTH SSC Subcommittee on Control of
Anticoagulation. The guidance statement is endorsed by
the following societies: the American Thrombosis and
Hemostasis Network (ATHN), the Anticoagulation
Forum (AC Forum), the Canadian Pediatric Thrombosis
and Hemostasis Network (CPTHN), the Dutch Society
for Thrombosis and Hemostasis (NVTH), the French
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Study Group in Hemostasis and Thrombosis, the Hemo-
stasis and Thrombosis Research Society (HTRS), the
National Blood Clot Alliance, the North American Spe-
cialized Coagulation Laboratory Association (NASCO-
LA), the North American Society on Thrombosis and
Hemostasis (NASTH), the Society for Vascular Medicine
(SVM), the Spanish Society of Thrombosis and Hemosta-
sis (SETH), and Thrombosis Canada.
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